{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:24:49Z","timestamp":1793759089817,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["5UH7MC30772-06-00"],"award-info":[{"award-number":["5UH7MC30772-06-00"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The web-based GMDI\/SERN PKU Nutrition Management Guideline, published before approval of pegvaliase pharmacotherapy, offers guidance for nutrition management of individuals with phenylketonuria (PKU) treated with dietary therapy and\/or sapropterin. An update of this guideline aims to provide recommendations that improve clinical outcomes and promote consistency and best practice in the nutrition management of individuals with PKU receiving pegvaliase therapy. Methodology includes: formulation of a research question; review, critical appraisal, and abstraction of peer-reviewed studies and unpublished practice literature; expert input through Delphi surveys and a Nominal Group process; and external review by metabolic experts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Recommendations, summary statements, and strength of evidence are included for each of the following topics: (1) initiating a pegvaliase response trial, (2) monitoring therapy response and nutritional status, (3) managing pegvaliase treatment after response to therapy, (4) education and support for optimal nutrition with pegvaliase therapy, and (5) pegvaliase therapy during pregnancy, lactation, and adolescence. Findings, supported by evidence and consensus, provide guidance for nutrition management of individuals receiving pegvaliase therapy for PKU. Recommendations focus on nutrition management by clinicians, as well as the challenges for individuals with PKU as a result of therapy changes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Successful pegvaliase therapy allows the possibility for individuals with PKU to consume an unrestricted diet while still maintaining the benefits of blood phenylalanine control. This necessitates a perspective change in education and support provided to individuals in order to achieve healthy nutrient intake that supports optimal nutritional status. The updated guideline, and companion Toolkit for practical implementation of recommendations, is web-based, allowing for utilization by health care providers, researchers, and collaborators who advocate and care for individuals with PKU. These guidelines are meant to be followed always taking into account the provider\u2019s clinical judgement and considering the individual\u2019s specific circumstances. Open access is available at the Genetic Metabolic Dietitians International (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/GMDI.org\">https:\/\/GMDI.org<\/jats:ext-link>) and Southeast Regional Genetics Network (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/managementguidelines.net\">https:\/\/managementguidelines.net<\/jats:ext-link>) websites.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02751-0","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T21:04:05Z","timestamp":1687467845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Nutrition management of PKU with pegvaliase therapy: update of the web-based PKU nutrition management guideline recommendations"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5304-0931","authenticated-orcid":false,"given":"Amy","family":"Cunningham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Splett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shideh","family":"Mofidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Bausell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrya","family":"Stembridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Kenneson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani H.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"2751_CR1","unstructured":"Regier DS, Greene CL (2000) Phenylalanine hydroxylase deficiency. In: Adam MP, Everman DB, Mirzaa GM, et al (editors) GeneReview. Seattle (WA): University of Washington, Seattle. 1993\u20132023"},{"key":"2751_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ymgme.2016.04.008","volume":"118","author":"RH Singh","year":"2016","unstructured":"Singh RH, Cunningham AC, Mofidi S, Douglas TD, Frazier DM, Hook DG, Jeffers L, McCune H, Moseley KD, Ogata B. Updated, web-based nutrition management guideline for PKU: an evidence and consensus based approach. Mol Genet Metab. 2016;118:72\u201383. https:\/\/doi.org\/10.1016\/j.ymgme.2016.04.008.","journal-title":"Mol Genet Metab"},{"key":"2751_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/PHMT.S49329","volume":"7","author":"JC Rocha","year":"2016","unstructured":"Rocha JC, MacDonald A. Dietary intervention in the management of phenylketonuria: current perspectives. Pediatr Health, Med Therap. 2016;7:155\u201363.","journal-title":"Pediatr Health, Med Therap"},{"key":"2751_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/nu13031040","volume":"13","author":"F Ilgaz","year":"2021","unstructured":"Ilgaz F, Marsaux C, Pinto A, Singh R, Rohde C, Karabulut E, G\u00f6kmen-\u00d6zel H, Kuhn M, MacDonald A. Protein substitute requirements of patients with phenylketonuria on BH4 treatment: a systematic review and meta-analysis. Nutrients. 2021;13:1040.","journal-title":"Nutrients"},{"key":"2751_CR5","unstructured":"Biomarin. European Commission Approves Palynziq (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 years or older. Available online: https:\/\/investors.biomarin.com\/2019-05-06-European-Commission-Approves-Palynziq-R-pegvaliase-injection-for-Treatment-of-Phenylketonuria-PKU-in-Patients-Aged-16-Years-or-Older (accessed on Jan 15, 2023)."},{"key":"2751_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40259-018-0292-3","volume":"32","author":"A Markham","year":"2018","unstructured":"Markham A. Pegvaliase: first global approval. BioDrugs. 2018;32:391\u20135. https:\/\/doi.org\/10.1007\/s40259-018-0292-3.","journal-title":"BioDrugs"},{"key":"2751_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","volume":"384","author":"N Longo","year":"2014","unstructured":"Longo N, Harding CO, Burton BK, Grange DK, Vockley J, Wasserstein M, Rice GM, Dorenbaum A, Neuenburg JK, Musson DG. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. The Lancet. 2014;384:37\u201344.","journal-title":"The Lancet"},{"key":"2751_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41436-018-0403-z","volume":"21","author":"N Longo","year":"2019","unstructured":"Longo N, Dimmock D, Levy H, Viau K, Bausell H, Bilder DA, Burton B, Gross C, Northrup H, Rohr F. Evidence-and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. Genet Med. 2019;21:1851\u201367. https:\/\/doi.org\/10.1038\/s41436-018-0403-z.","journal-title":"Genet Med"},{"key":"2751_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1365-2753.2011.01807","volume":"19","author":"RH Singh","year":"2013","unstructured":"Singh RH, Rohr F, Splett PL. Bridging evidence and consensus methodology for inherited metabolic disorders: creating nutrition guidelines. J Eval Clin Pract. 2013;19:584\u201390. https:\/\/doi.org\/10.1111\/j.1365-2753.2011.01807.","journal-title":"J Eval Clin Pract"},{"key":"2751_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ymgme.2019.02.007","volume":"112","author":"DM Frazier","year":"2014","unstructured":"Frazier DM, Allgeier C, Homer C, Marriage BJ, Ogata B, Rohr F, Splett PL, Stembridge A, Singh RH. Nutrition management guideline for maple syrup urine disease: an evidence-and consensus-based approach. Mol Genet Metab. 2014;112:210\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2019.02.007.","journal-title":"Mol Genet Metab"},{"key":"2751_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ymgme.2019.02.007","volume":"126","author":"E Jurecki","year":"2019","unstructured":"Jurecki E, Ueda K, Frazier D, Rohr F, Thompson A, Hussa C, Obernolte L, Reineking B, Roberts A, Yannicelli S. Nutrition management guideline for propionic acidemia: an evidence-and consensus-based approach. Mol Genet Metab. 2019;126:341\u201354.","journal-title":"Mol Genet Metab"},{"key":"2751_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ymgme.2020.10.001","volume":"131","author":"S Van Calcar","year":"2020","unstructured":"Van Calcar S, Sowa M, Rohr F, Beazer J, Setlock T, Weihe T, Pendyal S, Wallace L, Hansen J, Stembridge A. Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): an evidence-and consensus-based approach. Mol Genet Metab. 2020;131:23\u201337. https:\/\/doi.org\/10.1016\/j.ymgme.2020.10.001.","journal-title":"Mol Genet Metab"},{"key":"#cr-split#-2751_CR13.1","unstructured":"Graham RM, Wolman DM, Greenfield S, Steinberg E (2023) Clinical practice guidelines we can trust"},{"key":"#cr-split#-2751_CR13.2","unstructured":"The National Academies Press: Washington, D.C., 2011. (Access date 09 February, 2023). https:\/\/nap.nationalacademies.org\/catalog\/13058\/clinical-practice-guidelines-we-can-trust"},{"key":"2751_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","volume":"11","author":"P Nasa","year":"2021","unstructured":"Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol. 2021;11:116\u201329. https:\/\/doi.org\/10.5662\/wjm.v11.i4.116.","journal-title":"World J Methodol"},{"key":"2751_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.7748\/nr.2021.e1777","volume":"29","author":"R Mullen","year":"2021","unstructured":"Mullen R, Kydd A, Fleming A, McMillan L. A practical guide to the systematic application of nominal group technique. Nurse Res. 2021;29:14\u201320. https:\/\/doi.org\/10.7748\/nr.2021.e1777.","journal-title":"Nurse Res"},{"key":"2751_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-02086-8","volume":"16","author":"A Burlina","year":"2021","unstructured":"Burlina A, Biasucci G, Carbone MT, Cazzorla C, Paci S, Pochiero F, Spada M, Tummolo A, Zuvadelli J, Leuzzi V. Italian national consensus statement on management and pharmacological treatment of phenylketonuria. Orphanet J Rare Dis. 2021;16:1\u201318. https:\/\/doi.org\/10.1186\/s13023-021-02086-8.","journal-title":"Orphanet J Rare Dis"},{"key":"2751_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100771","author":"JC Rocha","year":"2021","unstructured":"Rocha JC, Bausell H, B\u00e9langer-Quintana A, Bernstein L, G\u00f6kmen-\u00d6zel H, Jung A, MacDonald A, Rohr F, van Dam E, Heddrich-Ellerbrok M. Development of a practical dietitian road map for the nutritional management of phenylketonuria (PKU) patients on pegvaliase. Mol Genet Metabol Rep. 2021. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100771.","journal-title":"Mol Genet Metabol Rep"},{"key":"2751_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ymgme.2021.05.006","volume":"133","author":"M Lah","year":"2021","unstructured":"Lah M, McPheron M. Palynziq clinic: one year and 43 patients later. Mol Genet Metab. 2021;133:250\u20136. https:\/\/doi.org\/10.1016\/j.ymgme.2021.05.006.","journal-title":"Mol Genet Metab"},{"key":"2751_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.1006","author":"S Sacharow","year":"2020","unstructured":"Sacharow S, Papaleo C, Almeida K, Goodlett B, Kritzer A, Levy H, Martell L, Wessel A, Viau K. First 15 years of pegvaliase clinic: experiences and outcomes. Mol Genet Metabol Rep. 2020. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.1006.","journal-title":"Mol Genet Metabol Rep"},{"key":"2751_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.10079","author":"D Adams","year":"2021","unstructured":"Adams D, Andersson HC, Bausell H, Crivelly K, Eggerding C, Lah M, Lilienstein J, Lindstrom K, McNutt M, Ray JW. Use of pegvaliase in the management of phenylketonuria: case series of early experience in US clinics. Mol Genet Metabol Rep. 2021. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.10079.","journal-title":"Mol Genet Metabol Rep"},{"key":"2751_CR21","unstructured":"FDA Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION - PALYNZIQ(pegvaliase-pqpz). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761079s000lbl.pdf (accessed on 7\/25\/2022)."},{"key":"2751_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1177392819857089","author":"T Hydery","year":"2019","unstructured":"Hydery T, Coppenrath VA. A comprehensive review of pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria. Drug Target Insights. 2019. https:\/\/doi.org\/10.1177\/1177392819857089.","journal-title":"Drug Target Insights"},{"key":"2751_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100905","author":"ER Vucko","year":"2022","unstructured":"Vucko ER, Havens KE, Baker JJ, Burton BK. Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower doses. Mol Genet Metabol Rep. 2022. https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100905.","journal-title":"Mol Genet Metabol Rep"},{"key":"2751_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ymgme.2021.06.002","volume":"133","author":"K Viau","year":"2021","unstructured":"Viau K, Wessel A, Martell L, Sacharow S, Rohr F. Nutrition status of adults with phenylketonuria treated with pegvaliase. Mol Genet Metab. 2021;133:345\u201351. https:\/\/doi.org\/10.1016\/j.ymgme.2021.06.002.","journal-title":"Mol Genet Metab"},{"key":"2751_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-015-0294-x","volume":"10","author":"AM Bosch","year":"2015","unstructured":"Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, Benmedjahed K, Regnault A. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015;10:1\u201314. https:\/\/doi.org\/10.1186\/s13023-015-0294-x.","journal-title":"Orphanet J Rare Dis"},{"key":"2751_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-017-0620-1","volume":"15","author":"E Jurecki","year":"2017","unstructured":"Jurecki E, Cunningham A, Birardi V, Gagol G, Acquadro C. Development of the US English version of the phenylketonuria\u2013quality of life (PKU-QOL) questionnaire. Health Qual Life Outcomes. 2017;15:1\u20136. https:\/\/doi.org\/10.1186\/s12955-017-0620-1.","journal-title":"Health Qual Life Outcomes"},{"key":"2751_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ymgme.2018.06.010","volume":"125","author":"R Zori","year":"2018","unstructured":"Zori R, Thomas JA, Shur N, Rizzo WB, Decker C, Rosen O, Li M, Schweighardt B, Larimore K, Longo N. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria. Mol Genet Metab. 2018;125:217\u201327. https:\/\/doi.org\/10.1016\/j.ymgme.2018.06.010.","journal-title":"Mol Genet Metab"},{"key":"2751_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.15","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16:188\u2013200. https:\/\/doi.org\/10.1038\/gim.2013.15.","journal-title":"Genet Med"},{"key":"2751_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","volume":"124","author":"J Thomas","year":"2018","unstructured":"Thomas J, Levy H, Amato S, Vockley J, Zori R, Dimmock D, Harding CO, Bilder DA, Weng HH, Olbertz J. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018;124:27\u201338. https:\/\/doi.org\/10.1016\/j.ymgme.2018.03.006.","journal-title":"Mol Genet Metab"},{"key":"2751_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ymgme.2019.08.004","volume":"128","author":"GY Berguig","year":"2019","unstructured":"Berguig GY, Martin NT, Creer AY, Xie L, Zhang L, Murphy R, Pacheco G, Bullens S, Olbertz J, Weng HH. Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain. Mol Genet Metab. 2019;128:422\u201330. https:\/\/doi.org\/10.1016\/j.ymgme.2019.08.004.","journal-title":"Mol Genet Metab"},{"key":"2751_CR31","unstructured":"Thomas JA, Jurecki E, Whitehall KB, Olbertz J, Wang B, Longo N, Harding CO, Burton BK, Rohr F, van Calcar S (2020) Dietary intakes and adverse events in pegvaliase-treated phenylketonuria adults who had low blood phenylalanine concentrations. Poster presented at Society for Inherited Metabolic Disorders annual meeting, April 2020, Austin Texas. Poster 183"},{"key":"2751_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/ajcn\/nqy08","volume":"108","author":"CE Berryman","year":"2018","unstructured":"Berryman CE, Lieberman HR, Fulgoni VL III, Pasiakos SM. Protein intake trends and conformity with the Dietary Reference Intakes in the United States: analysis of the National Health and Nutrition Examination Survey, 2001\u20132014. Am J Clin Nutr. 2018;108:405\u201313. https:\/\/doi.org\/10.1093\/ajcn\/nqy08.","journal-title":"Am J Clin Nutr"},{"key":"2751_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3945\/an.116.013821","volume":"8","author":"RR Wolfe","year":"2017","unstructured":"Wolfe RR, Cifelli AM, Kostas G, Kim I-Y. Optimizing protein intake in adults: interpretation and application of the recommended dietary allowance compared with the acceptable macronutrient distribution range. Adv Nutr. 2017;8:266\u201375. https:\/\/doi.org\/10.3945\/an.116.013821.","journal-title":"Adv Nutr"},{"key":"2751_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/ajmg.a.62574","volume":"188","author":"DA Bilder","year":"2022","unstructured":"Bilder DA, Arnold GL, Dimmock D, Grant ML, Janzen D, Longo N, Nguyen-Driver M, Jurecki E, Merilainen M, Amato G. Improved attention linked to sustained phenylalanine reduction in adults with early-treated phenylketonuria. Am J Med Genet A. 2022;188:768\u201378. https:\/\/doi.org\/10.1002\/ajmg.a.62574.","journal-title":"Am J Med Genet A"},{"key":"2751_CR35","doi-asserted-by":"publisher","first-page":"100507","DOI":"10.1016\/j.ymgmr.2019.100507","volume":"21","author":"S SriBhashyam","year":"2019","unstructured":"SriBhashyam S, Marsh K, Quartel A, Weng HH, Gershman A, Longo N, Thomas J, Zori R. A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: a study of patients\u2019 preferences. Mol Genet Metabol Rep. 2019;21:100507. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100507.","journal-title":"Mol Genet Metabol Rep"},{"key":"2751_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1006\/mgme.2000.3038","volume":"71","author":"R Koch","year":"2000","unstructured":"Koch R, Hanley W, Levy H, Matalon R, Rouse B, Trefz F, Guttler F, Azen C, Friedman E, Platt L. Maternal phenylketonuria: an international study. Mol Genet Metab. 2000;71:233\u20139. https:\/\/doi.org\/10.1006\/mgme.2000.3038.","journal-title":"Mol Genet Metab"},{"key":"2751_CR37","doi-asserted-by":"publisher","first-page":"100713","DOI":"10.1016\/j.ymgmr.2021.100713","volume":"26","author":"M Boyer","year":"2021","unstructured":"Boyer M, Skaar J, Sowa M, Tureson JR, Chapel-Crespo CC, Chang R. Continuation of pegvaliase treatment during pregnancy: a case report. Mol Genet Metabol Rep. 2021;26:100713. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100713.","journal-title":"Mol Genet Metabol Rep"},{"key":"2751_CR38","unstructured":"Kopesky JJ; Sperl NA. Case reports of successful pregnancies after temporary discontinuation of pegvaliase. Poster presented at Genetic Metabolic Dietitians International 2021 meeting (virtual) 2021."},{"key":"2751_CR39","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","volume":"120","author":"E Jurecki","year":"2017","unstructured":"Jurecki E, Cederbaum S, Kopesky J, Perry K, Rohr F, Sanchez-Valle A, Viau K, Sheinin M, Cohen-Pfeffer J. Adherence to clinic recommendations among patients with phenylketonuria in the United States. Mol Genet Metab. 2017;120:190\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2017.01.001.","journal-title":"Mol Genet Metab"},{"key":"2751_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100555","author":"F Rohr","year":"2020","unstructured":"Rohr F, Kritzer A, Harding CO, Viau K, Levy HL. Discontinuation of Pegvaliase therapy during maternal PKU pregnancy and postnatal breastfeeding: a case report. Mol Genet Metabol Rep. 2020. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100555.","journal-title":"Mol Genet Metabol Rep"},{"key":"2751_CR41","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1080\/13880209.2016.1185634","volume":"54","author":"S Babao\u011flu Ayda\u015f","year":"2016","unstructured":"Babao\u011flu Ayda\u015f S, \u015eirin S, Aslim B. Biochemical analysis of Centaurea depressa phenylalanine ammonia lyase (PAL) for biotechnological applications in phenylketonuria (PKU). Pharm Biol. 2016;54:2838\u201344. https:\/\/doi.org\/10.1080\/13880209.2016.1185634.","journal-title":"Pharm Biol"},{"key":"2751_CR42","unstructured":"EMA. Palynziq - European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/palynziq (accessed on 7\/25\/2022)."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02751-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02751-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02751-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T21:05:44Z","timestamp":1687467944000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02751-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2751"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02751-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"6 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HB, RHS, FR, and AC have received honoraria from BioMarin for participation in professional advisory groups. The authors declare no other conflicts of interest. Full disclosure of any sponsorship or competing interests by authors of publications cited, especially when referring to BioMarin, may be found in those papers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The Dephi surveys were conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Emory University (FWA#00005792,\u00a0Study #00051630). Informed consent was obtained from all subjects involved in the Delphi surveys.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"155"}}